The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
Harriet Oduya
Page 10 of 10 of this archive, newest first.
Archive — page 10
192 piecesThe named comparison we promised two years ago
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Independent analysis puts a SSA exenatide lot at 97.3%, against 93.3% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Why the bone question is harder than the muscle question
What the Journal would want measured before treating this as settled in either direction.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Seasonal use, holiday use, and the honest state of the evidence
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
PeptideMeter result on a Guangzhou semaglutide lot lands 1.0 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The shortage years, and what they taught about interruption
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
The dose that got you here and the dose that keeps you here
The commonest real-world strategy in this drug class is the least studied one.
Independent analysis puts a BCH semaglutide lot at 95.2%, against 91.2% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.